This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
COVID-19vaccines are extremely safe , and serious harms are rare. But rare does not mean the risk is zero; thus, we need a way to determine which people have plausible claims of harm from the vaccines, and we must then compensate them quickly and generously. By Dorit Reiss. Nevertheless, rare injuries do happen.
Centers for Disease Control and Prevention (CDC) is failing parents by preventing off-label use of our existing COVID-19vaccines in the under-five set. The CDC, through its vaccine provider agreements, prevents physicians and parents from pursuing off-label use of COVID-19vaccinations in young children.
In June 2022, after almost two years of debate over a potential COVID-19vaccine patent waiver, the World Trade Organization adopted the Ministerial Decision on the TRIPS Agreement (“WTO Decision”), which provided for a partial waiver of intellectual property rights. By Sarah Gabriele. appeared first on Bill of Health.
The Community Organized Relief Effort in Georgia, better known as CORE, had a major operational challenge to coordinate all the logistical issues of setting up mobile vaccinations for COVID-19 across an entire state and managing dozens of field teams at more than 100 different locations. THE PROBLEM. Enterprise Taxonomy:
Last month, the patent battle between COVID-19 mRNA vaccine manufacturers continued with BioNTech/Pfizer filing a strong defense and counter-claim to Moderna’s allegations of patent infringement. Interestingly, as of January 12, 2023, Moderna has listed 10 patents covering Spikevax (its mRNA vaccine) on its website.
As communities across the nation seek new ways to bring COVID-19vaccination rates up to levels that can more effectively mitigate the spread of variants, they are looking for new and better ways to reach those who are just hesitant, undecided or unaware of how to get vaccinated.
The American Medical Association (AMA) announced that the Current Procedural Terminology (CPT) code set has been updated by the CPT Editorial Panel to include vaccine and administration codes for pediatric doses of the COVID-19vaccine developed […].
The American Medical Association (AMA) today announced that the Current Procedural Terminology (CPT) code set has been updated by the CPT Editorial Panel to include vaccine and administration codes that are unique to a new formulation of […].
The vaccines also reduced infections and hospitalizations, which freed up hospital resources, researchers at the Commonwealth Fund and Yale School of Public Health concluded.
The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.
As the slower-than-expected COVID-19vaccine rollout continues around the United States, experts have noted the importance of the "last mile" – getting dosages into the arms of patients. "We took a customer live in four days last week specifically because of the COVIDvaccine," de Zwirek said.
Since the first days of the COVID-19 pandemic, employers, businesses, and other entities have anticipated litigation around tort claims associated with the novel coronavirus. Some respondents analyze how we got here — the specific conditions of the COVID-19 pandemic that have influenced and constrained potential litigation.
Has the worldwide distribution of COVID-19vaccines been impacted by patent rights? Tran , senior associate at Milbank LA, argue that the story is much more complicated — making vaccines involves much more than waiving patents, they explain. What other IP protections do COVIDvaccine manufacturers use?
The COVID-19 pandemic placed significant strain on providers, causing a demand for care that […]. The article The Year Ahead: Preparing For Widespread COVID-19Vaccine Deployment appeared first on electronichealthreporter.com.
The Court placed COVID-19 in the latter category. Although the OSHA case will now return to the Sixth Circuit for a decision on the merits of the challenges to the vaccine-or-test requirements, the Supreme Court’s analysis of the scope of OSHA’s authority is likely to drive the lower court’s decision.
We used our patient engagement technology from Luma Health to power this initiative because of our past success creating new workflows together, including a QR code-based patient check-in and screening process for our mass COVID-19vaccination site. In response, the patient gets a link to a short form on their phones.
The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.
Vaccinating as many people as possible to reduce the spread of respiratory illness that can be especially life-threatening for the youngest and oldest Americans is key, argues vaccine law professor Richard Hughes IV.
New guidance from CMS sets different vaccine deadlines for healthcare workers in half the country, which could create confusion. Further complicating compliance is Texas' current shield from any deadline.
By Jonathan Howard On June 29, 2021, Dr. Harriet Hall penned an essay on the website Science Based Medicine titled “A New COVID-19 Myth?” 6 This didn’t stop her from making a nearly identical podcast in May 2022 titled “Living with COVID,” 7 which declared “we now have all the necessary tools to end the COVID ‘emergency phase’.
By Kayum Ahmed, Julia Bleckner, and Kyle Knight In mid-May, the World Health Organization officially declared the “emergency” phase of the COVID-19 pandemic over. This pattern has had lethal consequences during the COVID-19 pandemic, harming efforts to advance global solidarity.
The regulator’s decision comes more than a year after the main part of the principal trial was completed, raising questions about the shot’s effectiveness against omicron.
On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. The unprecedented scope of the COVID-19 pandemic quickly gave rise to a surge of pledging activity, which is detailed in this article (see pp. Pandemic Pledges.
The companies' vaccine provided strong protection against severe illness in a large clinical trial. The long-awaited results could position it as a booster for people who have received other shots.
Vaccines are no longer our only medical intervention for preventing severe COVID-19. Older and medically vulnerable people who continue to face high risk of COVID-19 illness after vaccination should not be asked to wait in line behind adults who refused vaccines.
The agency pushed back plans to expedite review of the shot in children under 5, seeking more data on a third dose. An advisory meeting scheduled for next week has been postponed as a result.
Study results showed two shots of Moderna's vaccine led to similar immune responses as those observed in young adults, although protection against omicron was modest.
The companies said the FDA, in an unusual step, requested they submit the clinical trial data they currently have while testing of a third dose in children under 5.
The National Institutes of Health (NIH) is currently embroiled in a dispute over the ownership of patent rights to Moderna’s flagship mRNA COVID-19vaccine (mRNA-1273). If so, NIH, their employer, would be a co-owner of the vaccine technology and could, in theory, make it more broadly available around the world.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content